Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs

BSE4025.35184.6 (+4.81 %)

PREV CLOSE ( ) 3840.75

OPEN PRICE ( ) 3855.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 29373

TODAY'S LOW / HIGH ( )3840.75 4040.00

52 WK LOW / HIGH ( )3050.15 4072.35

NSE4016.35172.55 (+4.49 %)

PREV CLOSE( ) 3843.80

OPEN PRICE ( ) 3850.00

BID PRICE (QTY) 4016.35 (2062)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1155173

TODAY'S LOW / HIGH( ) 3836.05 4039.00

52 WK LOW / HIGH ( )3051 4074.4

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-10 1990

Management Info

Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director

Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

26Apr Divi's Laboratories surges on planning
Divi's Laboratories is currently trading at Rs. 3988.50, up by 147.75 po..

25Apr Divi's Laboratories planning for capac
Divi's Laboratories is in the process of entering into a long-term suppl..

25Apr Divi’s Laboratories informs about disc
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obliga..

11Apr Divi's Laboratories informs about cert
Divi's Laboratories has informed that it enclosed certificate dated Apri..

30Mar Divi’s Laboratories informs about clos
Pursuant to the Company’s Code of Conduct for Prevention of Insider Trad..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	3580	18081.5
Gross Profit	4900	23541
Operating Profit	5850	26966.9
Net Sales	18080	76253

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE) 8278.10 (1.76%)	M.Cap ( in Cr)19064.98
Abbott India (BSE) 25864.85 (0.54%)	M.Cap ( in Cr)54961.00
Astrazeneca Pharma I (BSE) 5415.40 (2.18%)	M.Cap ( in Cr)13538.50
Glaxosmithkline Phar (BSE) 2132.75 (3.26%)	M.Cap ( in Cr)36130.07
Ajanta Pharma (BSE) 2200.70 (2.94%)	M.Cap ( in Cr)27710.26

Shareholding Pattern

	PROMOTERS	51.92%
	MUTUAL FUNDS/UTI	14.28%
	NON-INSTITUTION	11.19%
	FI/BANKS/INSURANCE	7.24%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
ICICI Pru Nifty Pha...	6.73
Nippon India Nifty ...	6.72
ICICI Pru Nifty Hea...	5.90
Axis NIFTY Healthcare ETF	5.89
Aditya Birla SL Nif...	5.89
SBI Magnum Global F...	5.49
SBI LT Advantage Fu...	4.68

Risk Disclosures on Derivatives

Smart Quotes

DIVI'S LABORATORIES LTD.